Literature DB >> 8704096

Regulation of cytokine release by alveolar macrophages treated with interleukin-4, interleukin-10, or transforming growth factor beta.

G Zissel1, J Schlaak, M Schlaak, J Müller-Quernheim.   

Abstract

We evaluate the influence of IL-4, IL-10 and TGF-beta upon the release of IL-1 alpha, tumor necrosis factor-alpha (TNF-alpha), and IL-6 by lipopolisaccharide (LPS, 1 microgram/ml) stimulated alveolar macrophages (AM). IL-4 reduced TNF-alpha release, in a dose dependent manner, to 62% and IL-1 alpha release to 42% of LPS-stimulated AM without IL-4. IL-6 release was also suppressed (61%), however, with a biphasic dose response curve. IL-10 suppressed LPS induced release of IL-alpha and TNF-alpha to approximately 50% of control without affecting IL-6 release. When used at high concentrations, TGF-beta achieved moderate reductions of TNF-alpha and IL-1 alpha release. Low concentrations of LPS (0.1 microgram/ml), allowed a dose-dependent TGF-beta-induced suppression of TNF-alpha-release to approximately 80% of control. The combinations of IL-4 and IL-10 was more effective in suppressing IL-6 release, although the suppression was only weak. Other combinations of cytokines revealed no synergistic inhibitory activities. Our data demonstrate that IL-1 alpha and TNF-alpha release by AMs is down regulated by IL-4, IL-10, and TGF-beta. IL-6 release, however, can only be suppressed to some extent by a combination of IL-4 and IL-10.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8704096

Source DB:  PubMed          Journal:  Eur Cytokine Netw        ISSN: 1148-5493            Impact factor:   2.737


  7 in total

Review 1.  What do we mean by the term "inflammation"? A contemporary basic science update for sports medicine.

Authors:  A Scott; K M Khan; C R Roberts; J L Cook; V Duronio
Journal:  Br J Sports Med       Date:  2004-06       Impact factor: 13.800

2.  MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily.

Authors:  M R Bootcov; A R Bauskin; S M Valenzuela; A G Moore; M Bansal; X Y He; H P Zhang; M Donnellan; S Mahler; K Pryor; B J Walsh; R C Nicholson; W D Fairlie; S B Por; J M Robbins; S N Breit
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

3.  Interleukin-10 gene therapy-mediated amelioration of bacterial pneumonia.

Authors:  D F Morrison; D L Foss; M P Murtaugh
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

4.  Injury-induced GR-1+ macrophage expansion and activation occurs independently of CD4 T-cell influence.

Authors:  Fionnuala M O'Leary; Goro Tajima; Adam J Delisle; Kimiko Ikeda; Sinead M Dolan; Marc Hanschen; John A Mannick; James A Lederer
Journal:  Shock       Date:  2011-08       Impact factor: 3.454

5.  Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis.

Authors:  G Grünig; D B Corry; M W Leach; B W Seymour; V P Kurup; D M Rennick
Journal:  J Exp Med       Date:  1997-03-17       Impact factor: 14.307

6.  Imbalance of pro- and anti-inflammatory cytokines in pulmonary sarcoidosis.

Authors:  J Müller-Quernheim
Journal:  Mediators Inflamm       Date:  1996       Impact factor: 4.711

7.  A histopathologic study of the controlling role of T cells on experimental periodontitis in rats.

Authors:  Satoshi Izumi; Yasunori Yoshinaga; Hirotaka Nakamura; Akiko Takamori; Yuzo Takamori; Takashi Ukai; Chiaki Shiraishi; Yoshitaka Hara
Journal:  J Dent Sci       Date:  2018-04-11       Impact factor: 2.080

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.